Pfizer shares fall after Prevnar FDA delay

NEW YORK, Dec 31 (Reuters) – Pfizer Inc shares fell
1 percent on Thursday after it said a U.S. decision on whether
to approve the company’s new version of its big-selling Prevnar
vaccine that fights pneumonia and meningitis would push past
the deadline.

Leave a Reply